2016
DOI: 10.1073/pnas.1608461113
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Circulating tumor cells (CTCs) are established cancer biomarkers for the “liquid biopsy” of tumors. Molecular analysis of single CTCs, which recapitulate primary and metastatic tumor biology, remains challenging because current platforms have limited throughput, are expensive, and are not easily translatable to the clinic. Here, we report a massively parallel, multigene-profiling nanoplatform to compartmentalize and analyze hundreds of single CTCs. After high-efficiency magnetic collection of CTC from blood, a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
60
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 89 publications
(60 citation statements)
references
References 56 publications
0
60
0
Order By: Relevance
“…Park et al developed a method for molecular analysis of single CTCs after magnetic separation from blood[64]. Their nanowell array platform is able to compartmentalize CTCs into single cell wells and then perform multigene expression analyses using quantitative real-time PCR.…”
Section: Technologies For Circulating Tumor Cell Capture and Analysismentioning
confidence: 99%
“…Park et al developed a method for molecular analysis of single CTCs after magnetic separation from blood[64]. Their nanowell array platform is able to compartmentalize CTCs into single cell wells and then perform multigene expression analyses using quantitative real-time PCR.…”
Section: Technologies For Circulating Tumor Cell Capture and Analysismentioning
confidence: 99%
“…EGFR mutations were detected in 31 (84%) patients, corresponding to those present in matching tumor tissue (49). Finally, a recent publication by Park et al, used a nanotechnology based CTC detection platform in NSCLC patients (50). Using this highly sensitive device the authors were able to accurately detect each patient's known mutation on single CTCs.…”
Section: Egfr Mutations Status and Ctcsmentioning
confidence: 99%
“…A full cancer genome and transcriptome is present in each individual CTC and protein markers can be used for isolation or enumeration of them, therefore they represent an interesting source of tumor information where mutations and gene fusions can be found (12)(13)(14). Many studies have used enumeration of CTCs to predict recurrence or used cancer-derived biomarkers to follow therapy resistance (12,15).…”
Section: Circulating Tumor Cells (Ctcs)mentioning
confidence: 99%